OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL-Reference-Cited by-同舟云学术

OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL

Published:2019-04-23 Issue:14 Volume:25 Page:4493-4503
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Evans Kathryn,Duan JianXin,Pritchard Tara^ORCID,Jones Connor D.,McDermott Lisa,Gu Zhaohui,Toscan Cara E.^ORCID,El-Zein Narimanne,Mayoh Chelsea^ORCID,Erickson Stephen W.,Guo Yuelong,Meng Fanying,Jung Donald,Rathi Komal S.,Roberts Kathryn G.,Mullighan Charles G.^ORCID,Shia Chi-Sheng,Pearce Tillman,Teicher Beverly A.,Smith Malcolm A.,Lock Richard B.

Funder

NCI

NHMRC

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IN VIVO ACTIVITY OF THE SECOND-GENERATION PROTEASOME INHIBITOR IXAZOMIB AGAINST PEDIATRIC T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA XENOGRAFTS;Experimental Hematology;2024-02

2. Investigation of fatty acid metabolism in chronic lymphocytic leukemia to guide clinical outcome and therapy;Annals of Hematology;2023-12-27

3. A novel AKR1C3 specific prodrug AST-3424 and its combination therapy in hepatocellular carcinoma;Journal of Pharmacological Sciences;2023-06

4. Development of highly potent and specific AKR1C3 inhibitors to restore the chemosensitivity of drug-resistant breast cancer;European Journal of Medicinal Chemistry;2023-02

5. T-cell acute lymphoblastic leukemia: promising experimental drugs in clinical development;Expert Opinion on Investigational Drugs;2022-12-28